-
1
-
2
Comparative evaluation of immunoassays to improve access to diagnosis for Chagas disease in Colombia
Published 2019-10-01Get full text
Article -
3
A four-step process for building sustainable access to diagnosis and treatment of Chagas disease
Published 2019-08-01Get full text
Article -
4
-
5
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
Published 2021-07-01“…Funding: Through the Drugs for Neglected Diseases initiative: the Bill & Melinda Gates Foundation, the Republic and Canton of Geneva (Switzerland), the Dutch Ministry of Foreign Affairs (also known as DGIS; Netherlands), the Norwegian Agency for Development Cooperation (also known as Norad; Norway), the Federal Ministry of Education and Research (also known as BMBF) through KfW (Germany), the Brian Mercer Charitable Trust (UK), and other private foundations and individuals from the HAT campaign. …”
Get full text
Article -
6
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
Published 2022-08-01Get full text
Article -
7
How Clinical Research Can Contribute to Strengthening Health Systems in Low Resource Countries
Published 2020-03-01Get full text
Article -
8
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Published 2024-03-01Get full text
Article -
9
-
10
-
11
-
12
The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment
Published 2013-12-01Get full text
Article -
13
-
14
-
15
-
16
Evaluación del cambio del algoritmo de diagnóstico serológico para la enfermedad de Chagas en Colombia
Published 2023-10-01Get full text
Article -
17
Drug discovery and development for neglected diseases: the DNDi model
Published 2011-03-01“…Eric Chatelain, Jean-Robert IosetDrugs for Neglected Diseases Initiative (DNDi), Geneva, SwitzerlandAbstract: New models of drug discovery have been developed to overcome the lack of modern and effective drugs for neglected diseases such as human African trypanosomiasis (HAT; sleeping sickness), leishmaniasis, and Chagas disease, which have no financial viability for the pharmaceutical industry. …”
Get full text
Article -
18
Ravidasvir: equitable access through an alternative drug development pathway
Published 2021-11-01Get full text
Article -
19
Target Product Profile for a point-of-care diagnostic test for dermal leishmaniases
Published 2019-05-01Get full text
Article -
20